Would love your comments on the phase 2b trials Mozz and team
I did notice the placebo group had a 43% reduction in pain vs 55% for the LOR group. About a 10% difference...I'm trying to remember what our separation was like?
Even if this is a great drug there will still be many questions.
The phase 3 is not blinded, where can it be marketed. What would they have to do to satisfy FDA and EMA or would it just be licenced off and sold privately.
In that case is it really competition? There is of course space for more than 1 drug in this huge market.
Could it be an adjunct therapy?
It would be nice though if paradigm becomes the first DMOAD!
Trial PAR008 is on ANZCTR, page-56
-
- There are more pages in this discussion • 12 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
31.0¢ |
Change
0.035(12.7%) |
Mkt cap ! $108.4M | |||
| Open | High | Low | Value | Volume |
| 27.5¢ | 31.0¢ | 27.5¢ | $108.9K | 371.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1000 | 30.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 31.0¢ | 17420 | 5 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| PAR (ASX) Chart |